Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PainchekASX:PCK -8.70%40 Net Cash per Share is A$0.01 as of Dec. 2025, which is 100% below its 10-year median of 12.96. GuruFocus rates ASX:PCK with a GF Score™ of 40/100 and a GF Value™ of A$0.41 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 144 Healthcare Providers & Services companies, Painchek ranks worse than 63.19% on this metric.
The historical rank and industry rank for Painchek's Net Cash per Share or its related term are showing as below:
ASX:PCK'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.89 Med: 12.96 Max: 49.08
Current: 10.5
During the past 13 years, the highest Price-to-Net-Cash Ratio of Painchek was 49.08. The lowest was 5.89. And the median was 12.96.
ASX:PCK's Price-to-Net-Cash is ranked worse than 63.19% of 144
companies
in the Healthcare Providers & Services industry
Industry Median: 7.95
vs ASX:PCK: 10.50
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Painchek Net Cash per Share Related Terms
Painchek Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Painchek's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PCK vs VEEV, BTSG, HQY: Net Cash per Share Comparison
For the Health Information Services subindustry, Painchek's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Painchek Price-to-Net-Cash vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Painchek's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Painchek's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Painchek's Net Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Painchek (ASX:PCK) has a Net Cash per Share of A$0.01 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Painchek and its competitors. This is 100% below median its historical median of 12.96. Over the past decade, Painchek's Net Cash per Share has ranged from 5.89 to 49.08. According to the industry distribution chart, Painchek ranks #91 out of 144 companies in the Healthcare Providers & Services industry, placing it in the top 63.2%.
Is Painchek's Net Cash per Share too high?
Painchek's current Net Cash per Share of A$0.01 is 100% below median its 10-year median of 12.96. Over the past 10 years, this metric has ranged from a low of 5.89 to a high of 49.08. Based on the distribution chart, Painchek ranks #91 out of 144 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Painchek has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's Net Cash per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #91 out of 144 companies for Net Cash per Share. This places Painchek in the lower half of its industry. The industry median Net Cash per Share is 7.95. Historically, Painchek's own Net Cash per Share has ranged from 5.89 to 49.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Healthcare Providers & Services company?
The median Net Cash per Share among Healthcare Providers & Services companies is 7.95, based on 144 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Painchek and its competitors. For the Healthcare Providers & Services industry, the median Net Cash per Share is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current Net Cash per Share is A$0.01, which is 100% below median its own 10-year median of 12.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.41, compared to a current price of A$0.11 — trading 74.4% below its estimated fair value. The current Net Cash per Share is A$0.01, which is 100% below median its 10-year median of 12.96. Painchek's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Painchek (ASX:PCK), the current Net Cash per Share is A$0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Painchek (ASX:PCK) Overvalued in 2026?
Based on GuruFocus' analysis, Painchek stock appears to be undervalued.
The current stock price of A$0.11 is trading 74.4% below its estimated GF Value™ of A$0.41.
GuruFocus considers Painchek to be Possible Value Trap.
Key valuation signals for ASX:PCK:
Net Cash per Share: A$0.01 (100% below median its 10-year median of 12.96)
GF Value™: A$0.41 vs. price of A$0.11 (74.4% below fair value)
No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
40GF Score
Get the complete analysis for ASX:PCK
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PCK has been successfully added to your 
